Sonrotoclax Meets Primary ORR End Point in Mantle Cell Lymphoma
The safety profile of sonrotoclax was generally well-tolerated, and emergent toxicities were manageable in patients with mantle cell lymphoma.
Previous Post
Overcoming Barriers to Molecular Testing in NSCLC Care: Jorge Nieva, MD
Next Post
STAT+: Abridge CEO downplays impact of Epic’s new AI on call with customers
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago